Results 211 to 220 of about 1,093,896 (249)

Factors associated with drug adherence in psoriasis: a single‐center, retrospective, questionnaire‐based exploratory study in Bavaria

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Achieving sustained drug adherence in psoriasis remains challenging despite effective therapies. This exploratory study aims to investigate the care situation and factors associated with drug adherence in patients with moderate‐to‐severe psoriasis vulgaris (PsO). Patients and Methods A single‐center study was conducted
Negahr Jalili‐Tazeshahri, Gunnar Huppertz, Bernadett Kurz, Maria Isabel von Eichborn, Mark Berneburg, Tim Maisch, Dennis Niebel   +6 more
wiley   +1 more source

Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domains. [PDF]

Clin Rheumatol
Di Donato S, Alegre-Sancho JJ, Batalov A, Batalov Z, Bellando-Randone S, Coccia C, De Pinto M, Giuggioli D, Hughes M.   +8 more
europepmc   +1 more source

Insurance-driven switching and real-world treatment outcomes of Janus kinase inhibitors in alopecia areata: A retrospective cohort study. [PDF]

J Am Acad Dermatol
Engelking YT, Jabbari A.
europepmc   +1 more source

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

The FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén, Viktória Varga, Fatime Szalai, Risa Miyaura, Nóra Förhécz, Bálint Csikós, Rebeka Gelencsér, Zsófia Gábriel, Timea Komlódi, Katalin Dezső, Ildikó Krencz, Dorottya Moldvai   +11 more
wiley   +1 more source

Efficacy of Janus kinase inhibitors in the treatment of acute exacerbations of rheumatoid arthritis-associated interstitial lung disease: a retrospective observational case series. [PDF]

Front Immunol
Okamoto M, Fujikawa K, Mihara T, Doi S, Tomari S, Koga T, Kido T, Sakamoto N, Mizokami A, Mukae H, Kawakami A.   +10 more
europepmc   +1 more source

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes, Lian F. van der Gang, Daphne S. Bakker, C. F. den Hartog Jager, Marlies de Graaf, Marjolein S. de Bruin‐Weller, Femke van Wijk, Edward F. Knol   +7 more
wiley   +1 more source

Multilingual Digital Search Behavior Reveals Cultural Disparities in Vitiligo Information Needs in Germany

International Journal of Dermatology, EarlyView.
Multilingual vitiligo‐related Google search queries in Germany (October 2019–May 2023) were extracted and thematically coded across German, English, Turkish, Arabic, Russian, and Polish. Relative patterns highlighted language‐specific emphases in treatment information, camouflage, depigmentation, psychosocial burden, and faith/home‐remedy terms ...
Lilian Rauch, Christine Gasteiger, Markus Böhm, Georg Pliszewski, Tilo Biedermann, Alexander Zink   +5 more
wiley   +1 more source

Venous Thromboembolism Risk Following Total Joint Arthroplasty in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors Versus Tumor Necrosis Factor Inhibitors: A Propensity Score-Matched Cohort Study. [PDF]

J Clin Med
Kamran R, Chaudhary M, Herbert M, Sridharan M, Hori KR, Razick D, Blackburn A, Jensen A, Christ AB.   +8 more
europepmc   +1 more source

Impact of Dupilumab and Upadacitinib Treatment on Epigenetic and Transcriptomic Alterations in Skin‐Homing T Cells of Atopic Dermatitis Patients

Clinical &Experimental Allergy, EarlyView.
Ahmed M. I. Elfiky, Hidde M. Smits, Marlot van der Wal, Coco Dekkers, Celeste M. Boesjes, Julia Drylewicz, Marjolein de Bruin‐Weller, Femke van Wijk   +7 more
wiley   +1 more source

Early On‐Treatment Change in SALT as a Pragmatic Predictor of Ritlecitinib Response in Moderate‐To‐Severe Alopecia Areata: A Real‐World Cohort Study

International Journal of Dermatology, EarlyView.
Ritlecitinib induced rapid clinical improvement in moderate‐to‐severe alopecia areata in real‐world practice. Early change in SALT at Week 12 strongly discriminated Week‐24 responders, supporting a pragmatic treat‐to‐target checkpoint, alongside improvements in clinician‐reported and patient‐reported outcomes and a favorable safety profile.
Giuseppe Gallo, Isotta Giunipero di Corteranzo, Pietro Quaglino, Simone Ribero, Francois Rosset   +4 more
wiley   +1 more source